Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $100.96, for a total transaction of $706,720.00. Following the sale, the insider directly owned 31,771 shares in the company, valued at $3,207,600.16. The trade was a 18.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joana Goncalves also recently made the following trade(s):
- On Thursday, October 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00.
- On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86.
Oruka Therapeutics Stock Down 5.8%
Shares of NASDAQ ORKA traded down $6.11 on Monday, reaching $99.24. 989,987 shares of the company’s stock traded hands, compared to its average volume of 1,082,544. Oruka Therapeutics, Inc. has a 12 month low of $25.23 and a 12 month high of $115.51. The business’s 50 day simple moving average is $89.68 and its two-hundred day simple moving average is $72.36. The company has a market cap of $6.73 billion, a price-to-earnings ratio of -47.03 and a beta of -0.34.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). Analysts forecast that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Oruka Therapeutics in the second quarter worth approximately $474,916,000. Jupiter Topco LLC purchased a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $130,968,000. Bank of America Corp DE bought a new position in Oruka Therapeutics during the second quarter valued at approximately $33,578,000. Braidwell LP bought a new position in Oruka Therapeutics during the second quarter valued at approximately $26,473,000. Finally, Atika Capital Management LLC bought a new position in Oruka Therapeutics during the first quarter valued at approximately $11,277,000. 56.44% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of analysts have weighed in on the stock. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. HC Wainwright reiterated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Wedbush reiterated an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Finally, Guggenheim reiterated a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a report on Monday, October 26th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $141.80.
Get Our Latest Research Report on ORKA
Oruka Therapeutics Company Profile
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
